Regulus Therapeutics
RGLS
#7458
Rank
C$0.78 B
Marketcap
C$11.34
Share price
0.00%
Change (1 day)
442.99%
Change (1 year)

Earnings for Regulus Therapeutics (RGLS)

Earnings in 2025 (TTM): -C$66.2 Million

According to Regulus Therapeutics's latest financial reports the company's current earnings are N/A. In 2024 the company made an earning of -C$64.2 Million a decrease over its 2023 earnings that were of -C$40.9 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Regulus Therapeutics from 2012 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -C$66.2 Million3.12%
2024 -C$64.2 Million56.97%
2023 -C$40.9 Million6.51%
2022 -C$38.4 Million2.53%
2021 -C$37.46 Million93.59%
2020 -C$19.35 Million-15.41%
2019 -C$22.87 Million-64.46%
2018 -C$64.35 Million-33.26%
2017 -C$96.41 Million-13.98%
2016 -C$0.12 Billion44.77%
2015 -C$77.42 Million-1.63%
2014 -C$78.71 Million203.6%
2013 -C$25.93 Million8.65%
2012 -C$23.86 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sanofi
SNY
C$10.64 B-16,247.25%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
C$2.25 B-3,521.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
C$13.33 B-20,334.46%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
C$20.37 B-31,017.79%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
C$13.91 B-21,208.18%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sangamo Therapeutics
SGMO
-C$0.16 Billion 132.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
-C$0.17 Billion 148.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
C$1.20 B-1,933.62%๐Ÿ‡บ๐Ÿ‡ธ USA